Fairytale ending? Mythic flags new approach to improving ADC

December 2021 saw the launch of a new US based biotech, Mythic Therapeutics, with an oversubscribed Series B financing round of US$103m.

Related Keywords

China , Chinese , Brian Fiske , , Global Investors , Venrock Healthcare Capital Partners , Foresite Capital , Perceptive Advisors , Highside Capital , Bio Developments , Pipelines , Antibody Drug Conjugates , Lung Cancer , Payload , Drinker ,